What Espasmodel Compuesto Treats: Main Uses and Benefits

Espasmodel Compuesto is indicated for the symptomatic management of discomfort associated with involuntary muscle contractions and pain in smooth muscle tissue. This medication is used to manage pain related to conditions of the gastrointestinal and genitourinary tracts. Clinical scenarios where this product may be used include the temporary relief of symptoms associated with intestinal spasms, biliary colic, ureteral colic, and dysmenorrhea (painful menstruation).

Its use is intended to assist in the reduction of pain and the easing of associated muscle spasm. The medication is formulated to assist in the temporary management of acute spasmodic pain.

Quick Fact: Relief for Smooth Muscle Spasms and associated pain.

Who Can and Cannot Use Espasmodel Compuesto?

Eligibility to use Espasmodel Compuesto (Pargeverine and Clonixinate of Lysine) is strictly governed by the official regulatory guidelines for its active components, defining groups for whom the medicine is contraindicated or not recommended.

Absolute Contraindications

Use is strictly prohibited for patients with certain pre-existing conditions, including Glaucoma, Myasthenia Gravis, Severe Hepatic Impairment, and Severe Renal Failure. It is also contraindicated in individuals with Hyperlysinemia and those experiencing Active Gastrointestinal Bleeding.

Age and Developmental Restrictions

Pregnancy and Lactation

Use during pregnancy is not recommended or advised to be avoided. Similarly, the medicine is not recommended while breastfeeding due to a lack of established safety data for the components in these populations.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Espasmodel Compuesto based on its dual composition (an antispasmodic and an NSAID-like analgesic).

Contraindicated Combinations and Key Interaction Classes

The official profile specifies that interactions can occur through metabolic alteration via the CYP2C9 enzyme pathway. Furthermore, the oral formulation requires the separation of administration in time from certain Antacids or Sucralfate to prevent interference with its absorption. The regulatory documentation notes that the severity of interaction-related effects is increased for elderly patients and in those with pre-existing renal impairment when co-administered with nephrotoxic substances.

Espasmodel Compuesto acts through a dual pathway mechanism, simultaneously modulating smooth muscle contractility and influencing glandular function. Component A operates as a competitive antagonist at the M3 muscarinic acetylcholine receptor. This receptor blockade reduces cholinergic signal transduction in visceral smooth muscle cells, resulting in a decreased frequency and amplitude of contractions. Component B acts as a phosphodiesterase inhibitor, which increases intracellular cyclic adenosine monophosphate (cAMP) levels in specific target cells. The resulting elevation in cAMP activates protein kinase A (PKA). This cascade subsequently leads to the phosphorylation of myosin light chain kinase (MLCK), promoting its inactivation. This combined inhibition of the contractile cascade modulates peristaltic patterns. The net physiological consequence of this dual action is a decrease in smooth muscle spasm.

Instruction Map: How to use Espasmodel Compuesto — Official Administration Guidelines

Administration Scope

Route of administration: Oral (via swallowing of the tablet).

Dosing schedule: The standard adult regimen involves taking one to two tablets per single administration. The established maximum permitted daily dose is six tablets within a 24-hour period.

Timing in relation to meals: Administration is often recommended to occur with or immediately after meals to align with usage guidelines for the analgesic component.

Preparation requirements: The coated tablet must be taken whole and intact; it should not be crushed, broken, or chewed.

Age-group administration rules: Specific use is generally restricted to individuals older than 10 to 12 years. Official labeling recommends caution when administering to older adults due to the potential for altered organ function.

Special procedural conditions: The treatment is designated for short-term, symptomatic use. If relief is not achieved or symptoms persist for longer than 10 days, the necessity of continued use must be medically re-evaluated.

Instruction Classifications (High-Level)

Administration method type: Oral Tablet

Frequency pattern: Multiple daily doses (up to four times per day).

Use-context constraints: Defined short-term duration and explicit daily maximum dosage limits.

Resulting Procedural Structure

Official step sequence:

• Ingest the prescribed dose of one to two tablets (Pargeverine 10 mg / Clonixinate of Lysine 125 mg).
• Swallow the tablet whole with a glass of liquid, ideally consumed with a meal.
• Adhere to the established frequency, ensuring no more than six tablets are taken within 24 hours.
• Reassess the need for continued treatment if symptomatic use exceeds 10 days.

Connection to the overall use protocol: The official instructions establish a structured protocol that strictly defines the appropriate numerical dose, the maximum frequency of administration, and temporal limits for treatment duration, thereby formalizing the use of the medicine.

Research Evidence / Overview of Studies for Espasmodel Compuesto

Evidence for use in Painful Menstruation (Primary Dysmenorrhea)

Research exploring how symptoms change over time in painful menstruation, a condition characterized by fluctuating or episodic manifestations, was studied for this medication. Studies, including Randomized Controlled Trials (RCTs) and double-blind crossover designs, included adult women. This research examined patient-reported outcomes describing perceived discomfort and other systemic or functional imbalances that often accompany menstrual pain.

The findings describe patterns observed in studies exploring the measurement of pain intensity when comparing the Clonixinate of Lysine component to a placebo. Research highlights changes measured during the study period, reporting how symptoms were observed in the populations during the study period. What remains uncertain is the full context regarding the combined formulation, as evidence is largely derived from trials that only examined the single analgesic component, Clonixinate of Lysine. Long-term effects are not fully established, as follow-up durations were typically limited to several consecutive menstrual cycles.

Evidence for use in Acute Colic and Spasms (Ureteral and Renal)

The evidence for the use of this medicine in conditions associated with acute or disruptive episodes, such as ureteral or renal colic, was observed in certain clinical trials and observational reports. This research examined outcomes related to physical discomfort in adult patients presenting with symptoms where the pain becomes more noticeable. Studies monitored outcomes such as the change in pain scores (VAS) at short, defined intervals and the use of rescue medication.

Certainty remains low regarding the specific oral, dual-component formulation for this acute indication. Most research describing short-term changes focuses on the injectable form of the analgesic, not the combined oral product. Data are still emerging, and comparative evidence is lacking on how this combination was studied against other standards of care within the same research scenarios.

What is Still Uncertain About the Research for Espasmodel Compuesto

Research highlights what is known and what is still uncertain about this medicine. A key limitation is the absence of comprehensive head-to-head comparative evidence for the specific dual-drug combination (Pargeverine and Clonixinate of Lysine) versus the single active ingredients, or against other standard treatments for the full range of indications. Evidence quality varies across studies, and the reliance on extrapolation from studies of the individual components means the certainty remains low regarding the full scope of the combined product’s effects in specific patient groups or over extended periods.

Common questions about Espasmodel Compuesto (FAQ)

Q: Is Espasmodel Compuesto the same as regular Espasmodel?

Official documentation describes Espasmodel Compuesto as containing two active ingredients: the antispasmodic Pargeverine and the analgesic Clonixinate of Lysine. Because of this dual composition, the 'Compuesto' version is described as pharmacologically distinct due to this dual composition.

Q: Are there any common side effects people report with Espasmodel Compuesto?

Regulatory documents classify certain adverse reactions by frequency. Side effects such as dry mouth, headache, and mild gastrointestinal discomfort are officially listed as common effects.

Q: Can Espasmodel Compuesto cause drowsiness or affect driving?

Regulatory information indicates that this medication is associated with nervous system effects such as dizziness and lightheadedness. Due to this potential, official warnings advise that the medication may impair the ability to perform tasks that require mental alertness, such as driving or operating machinery.

Q: Does Espasmodel Compuesto interact with common vitamins or supplements?

Official interaction information primarily lists other prescription medications. However, official sources often include a general warning that the effects of the medicine may be altered by concomitant use with certain herbal products or supplements. If there are concerns about taking the medication with specific supplements, the product label indicates that a healthcare professional can provide guidance.

Q: Can older adults use Espasmodel Compuesto?

Official documents consistently state that the medication should be used with caution in older adults. This caution is due to the potential for an increased risk of severe adverse events, particularly gastrointestinal and renal effects, as noted in the official safety information.

Q: Can children or adolescents use Espasmodel Compuesto?

Official labeling generally states that use is not recommended or not established for individuals under the age of 18. Some documents specify restrictions for individuals below the age of 10 to 12 years.

Q: Why is this medication called 'Compuesto' (Compound)?

The term 'Compuesto' is used in the official pharmacological classification to describe its nature as a dual-action combination. This refers to the fact that the medicine contains two distinct active ingredients: an antispasmodic and an analgesic.

Q: If I have kidney problems, is Espasmodel Compuesto generally considered appropriate?

The medication is strictly contraindicated in patients with Severe Renal Failure. Furthermore, official warnings caution against its use in patients with other pre-existing renal impairment due to the potential for increased adverse effects related to the medicine's components.

Q: Can Espasmodel Compuesto interact with medicines for acid reflux?

Official documentation states that the administration of the tablet must be separated in time from certain agents like Antacids or Sucralfate. This procedure is advised to avoid interference with the drug's absorption.

Q: Is Espasmodel Compuesto safe for people with stomach ulcers?

Official warnings document a potential for serious gastrointestinal risk associated with the NSAID component. The regulatory safety profile mentions potential adverse events such as gastrointestinal ulceration, bleeding, and perforation.

Q: What organ systems are primarily affected by Espasmodel Compuesto?

Regulatory documents describe the documented effects of the medication as spanning the Gastrointestinal, Nervous, Ocular, and Urinary systems. This range of effects is consistent with the pharmacological actions of both the antispasmodic and the analgesic components.

Q: What happens if I miss a scheduled dose of Espasmodel Compuesto?

Standard regulatory guidance describes a protocol where a missed dose should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. Guidance states that in this instance, the missed dose should be skipped, and taking a double dose is not recommended.

Q: Is it normal to feel dry mouth after taking Espasmodel Compuesto?

Dry mouth is officially listed as a common adverse effect in regulatory documents. This classification indicates that it is one of the more frequently observed side effects associated with the medication's antispasmodic component.

Q: Is there a risk of dependency or addiction with Espasmodel Compuesto?

The official classification of its components as a non-opioid, antispasmodic-analgesic combination indicates that it is not classified as a controlled substance and is not described as carrying a formal risk of dependency or addiction in regulatory documents.

Q: Is it known if alcohol consumption affects how Espasmodel Compuesto works?

Regulatory warnings indicate that alcohol consumption can potentially increase or worsen certain side effects of the medication.

Q: What official health bodies have reviewed or approved Espasmodel Compuesto?

The regulatory basis for the medication is defined by National Medicines Agencies in the countries where it is approved. These authoritative bodies review and approve the official safety and efficacy documentation.

Q: Is Espasmodel Compuesto typically prescribed for long-term or short-term use?

Official guidelines state the treatment is designated for short-term, symptomatic use only. The necessity of continued use must be medically re-evaluated if symptoms persist beyond a specified duration, such as 10 days.

Q: What is the difference between an analgesic and an antispasmodic, as related to this drug?

Official descriptions define the analgesic component (Clonixinate of Lysine) as acting to reduce pain perception. The antispasmodic component (Pargeverine) acts to relax constricted smooth muscles, thereby addressing the physical cause of the discomfort.

Q: Does Espasmodel Compuesto typically cause nausea or stomach upset?

Nausea is officially documented as an adverse effect in the regulatory safety profile. The NSAID component is also associated with common gastrointestinal discomfort in official summaries.

Q: Is Espasmodel Compuesto primarily used for digestive or muscular spasms?

The therapeutic goal of the medicine is the symptomatic relief of pain arising from smooth muscle tissues. These tissues are found in multiple areas, including the gastrointestinal, urinary, and reproductive tracts.

Q: Why do some people experience blurred vision after taking this medication?

Blurred vision is listed as an officially documented side effect in the safety profile. This effect is typically linked to the anticholinergic action of the Pargeverine component of the drug.

Q: If I am taking a sedative, does Espasmodel Compuesto cause an interaction concern?

Official warnings caution that taking this medicine with other drugs that cause drowsiness (central nervous system depressants, which includes many sedatives) can potentially worsen this effect.

Q: Is it true that Espasmodel Compuesto can be used for period pain?

Official documentation includes studies examining its use for conditions like Primary Dysmenorrhea (painful menstruation), which is consistent with the drug’s use for spasms in the reproductive tract.

Q: What should be done if an accidental overdose of Espasmodel Compuesto occurs?

Standard regulatory guidance provided in patient information states that in the event of an overdose, an individual should seek emergency medical attention immediately and contact a poison control center.

Q: Are there specific storage instructions for Espasmodel Compuesto that patients should know?

Official regulatory documents require storage at an ambient temperature not exceeding 30 C. The medication must be protected from excessive heat and humidity, and the container should be kept tightly closed.

Q: How does the drug help with 'visceral' pain, as mentioned in some sources?

Official descriptions state the drug provides relief by two mechanisms: decreasing smooth muscle spasm (cramping) and reducing pain perception. This dual action primarily targets discomfort arising from visceral (internal organ) hypermotility.

Q: Is the onset of action different when taken with food?

Official guidance often recommends taking the tablet with or immediately after meals. This instruction is based on usage guidelines, typically to reduce the potential for gastrointestinal side effects or address absorption issues related to the analgesic component.

Q: Does Espasmodel Compuesto carry any specific warnings for individuals with heart conditions?

Official safety information notes an increased risk of serious cardiovascular thrombotic events (such as heart attack or stroke), particularly when use is prolonged. The drug is also contraindicated in individuals with certain severe heart conditions.

Q: What is the general safety classification of Espasmodel Compuesto according to regulatory agencies?

Official documents classify the medicine as a combination drug belonging to the antispasmodic-analgesic class. Its regulated use requires adhering to a defined short-term duration and strict daily maximum dosage limits defined by regulatory agencies.

Official Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing Espasmodel Compuesto to maintain its stability and integrity.

Like all medicines, Espasmodel Compuesto must be kept out of the sight and reach of children.

For disposal, the unused or expired product should be discarded according to local regulations. Community-based drug take-back programs are the recommended method. If such programs are unavailable, disposal should follow established guidelines for non-hazardous household waste.